Webcast, 12 November 2025
Important information
The information contained in this document has not been verified by an independent source. It should be taken with caution, and no assurance or guarantee is given (either explicit or implied) regarding the fairness, accuracy, completeness or correctness of the information or opinions contained herein. Neither Ypsomed Holding AG nor advisors or affiliates of Ypsomed Holding AG shall be liable in any way for losses occurred in conjunction with the use of this document, its contents or any other connection with this document. This document is neither an offer (or part of an offer) for the sale, nor a solicitation for the purchase of shares, and neither the document nor parts thereof form the basis of any contract or otherwise obligation. This document contains future-oriented statements which include uncertainties and risks. Such statements are indicated by such words as "could", "planned", "expected", "believed" and similar expressions or their context. These statements are made based on current knowledge and current assumptions. Due to a variety of different factors, the actual future results, developments or events may deviate considerably from those mentioned here. There is no obligation whatsoever to update future-oriented statements.
Our purpose is to make selfcare simpler and easier
Ypsomed benefits from structural growth drivers
Thanks to its clear strategic focus and solid structure, Ypsomed is uniquely positioned to benefit from significant growth in the end market
Pure-play injection specialist
Innovation leadership
Operational excellence
Strong
financials
Ypsomed is a pure-play injection specialist
Pure-play injection specialist
Innovation leadership
Operational excellence
Strong
financials
Ypsomed has completed its transformational journey to become a pure-play self-injection specialist
Ypsomed is now a pure play self-injection specialist
2025 2025 2024 2023 2022Completion of the sale of Ypsotec
Completion of the sale of the diabetes care business
Completion of the sale of the pen needle and BGM business
Completion of the sale of the DiaExpert retail business in Germany
Transformation from matrix structure to an organization with product areas
Ypsomed's new starting point - Delivery Systems generated revenue of CHF 267 million in the first half of the financial year 2025/26
Revenue contribution
HY 2025/26 (in mCHF)
Revenue contribution
mid-term
21
75
267
Delivery Systems Diabetes Care Other
Ypsomed is a leader in the innovation of delivery systemsPure-play injection specialist
Innovation leadership
Operational excellence
Strong
financials
Ypsomed has the widest range of self-injection solutions on the market